| CAS NO: | 1011301-29-3 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 491.09 |
|---|---|
| Formula | C25H35ClN4O2S |
| CAS No. | 1011301-29-3 (HCl); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 49 mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| Solubility (In vivo) | Tenovin-6 HCl; Tenovin 6 HCl; Tenovin6 HCl |
| General | Tenovin-6 is a more water-soluble analog of tenovin-1. Tenovin-6 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 in vitro with IC50 of 21 μM, 10 μM, and 67 μM, respectively. |
|---|---|
| Animal model | ARN8 melanoma cells were injected into the flank of SCID mice and allowed to develop into tumors. |
| Formulation | |
| Dosages | 50 mg/kg |
| Administration | i.p. |
| Reference | [1] Lain S, et al. Cancer Cell, 2008, 13(5), 454-463. |
m.cnreagent.com